Last updated on October 2018

Phase I Trail of Super-Selective Intra-Arterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Cancer of the Head and Neck (Squamous Cell Carcinoma, Including Nasopharyngeal Cancer, and Adenoid Cystic Carcinoma)


Brief description of study

This is a clinical trial aimed to determine the best tolerated dosage of Cetuximab into arteries for the treatement of un-resectable recurrent head and neck cancer. Cetuximab belongs in a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A high percentage of head and neck cancers over-express EGFR. Therefore, by stopping this receptor, we predict that it may be able to slow or stop the growth of the tumor and increase its responsiveness to therapy. Further, we hope the Intra-Arterial delivery method will allow a higher dose of cetuximab to your tumor, while limiting exposure of the drug to the rest of the body.

 

Clinical Study Identifier: TX213562

Find a site near you

Start Over

Northwell Health Clinical Trials Office

1981 Marcus Ave. Suite E110 Lake Success, NY United States
  Connect »